Drug General Information |
Drug ID |
D01LCC
|
Former ID |
DND000006
|
Drug Name |
PF-4217903
|
Synonyms |
PF-04217903
|
Drug Type |
Small molecular drug
|
Indication |
Cancer [ICD9: 140-229; ICD10:C00-C96]
|
Phase 1 |
[1]
|
Company |
Pfizer
|
Structure |
|
Download
2D MOL
3D MOL
|
Formula |
C19H16N8O
|
Canonical SMILES |
C1=CC2=C(C=CC(=C2)CN3C4=NC(=CN=C4N=N3)C5=CN(N=C5)CCO)N=<br />C1
|
InChI |
1S/C19H16N8O/c28-7-6-26-12-15(9-22-26)17-10-21-18-19(23-17)27(25-24-18)11-13-3-4-16-14(8-13)2-1-5-20-16/h1-5,8-10,12,28H,6-7,11H2
|
InChIKey |
PDMUGYOXRHVNMO-UHFFFAOYSA-N
|
PubChem Compound ID |
|
PubChem Substance ID |
29212271, 54248092, 99436977, 103905666, 124756993, 125011823, 125163798, 131480678, 134964423, 135653868, 135685260, 135685261, 135685280, 136340178, 136367293, 136920363, 137276005, 140816092, 143499148, 143499149, 152235007, 152237698, 152258340, 160647178, 162011939, 162037429, 162202551, 163312449, 163345958, 163907943, 164045116, 164764187, 170484567, 172113563, 177748688, 186022475, 198969694, 223402404, 223617434, 223705036, 224378934, 226471317, 247681667, 251963200, 252216038, 252216039, 252451594, 252543331
|
Target and Pathway |
Target(s) |
Hepatocyte growth factor receptor |
Target Info |
Inhibitor |
[2]
|
KEGG Pathway
|
Ras signaling pathway
|
Rap1 signaling pathway
|
Cytokine-cytokine receptor interaction
|
Endocytosis
|
PI3K-Akt signaling pathway
|
Axon guidance
|
Focal adhesion
|
Adherens junction
|
Bacterial invasion of epithelial cells
|
Epithelial cell signaling in Helicobacter pylori infection
|
Malaria
|
Pathways in cancer
|
Transcriptional misregulation in cancer
|
Proteoglycans in cancer
|
MicroRNAs in cancer
|
Renal cell carcinoma
|
Melanoma
|
Central carbon metabolism in cancer
|
Pathway Interaction Database
|
Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)
|
Arf6 signaling events
|
Signaling events mediated by TCPTP
|
Posttranslational regulation of adherens junction stability and dissassembly
|
Direct p53 effectors
|
Syndecan-1-mediated signaling events
|
Stabilization and expansion of the E-cadherin adherens junction
|
a6b1 and a6b4 Integrin signaling
|
FGF signaling pathway
|
Regulation of retinoblastoma protein
|
Reactome
|
Sema4D mediated inhibition of cell attachment and migration
|
WikiPathways
|
TGF beta Signaling Pathway
|
Signaling of Hepatocyte Growth Factor Receptor
|
Focal Adhesion
|
Extracellular vesicle-mediated signaling in recipient cells
|
Signaling Pathways in Glioblastoma
|
miR-targeted genes in squamous cell - TarBase
|
miR-targeted genes in muscle cell - TarBase
|
miR-targeted genes in lymphocytes - TarBase
|
miR-targeted genes in epithelium - TarBase
|
Semaphorin interactions
|
References |
REF 1 | ClinicalTrials.gov (NCT00706355) A Study of PF-04217903 in Patients With Advanced Cancer. U.S. National Institutes of Health. |
---|
REF 2 | Sensitivity of selected human tumor models to PF-04217903, a novel selective c-Met kinase inhibitor. Mol Cancer Ther. 2012 Apr;11(4):1036-47. |